Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature ...

CBC Group, Asia's largest healthcare asset management firm, has acquired UCB's neurology and allergy business in China in ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. <li /> Ne ...

DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...

UCB’s Bimzelx (bimekizumab-bkzx) has been approved by the US Food and Drug Administration (FDA) to treat active ...

UCB bangs drum for epilepsy drug in videos about ‘sound of profound’ seizure reduction Lorcaserin, which was developed by ...

Zealand Pharma shares rose as much as 8.5% intraday, taking its year-to-date gain to about 130% and momentarily exceeding the performance of Belgian biotech UCB SA. Zealand Pharma this week said ...

Swansea University has helped secure £22.4 million in funding from the Biotechnology and Biological Sciences Research Council ...